{"id":"NCT01649804","sponsor":"Hoffmann-La Roche","briefTitle":"A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis","officialTitle":"A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG-TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2012-07-25","resultsPosted":"2016-09-22","lastUpdate":"2016-11-04"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"RoActemra/Actemra single arm","type":"EXPERIMENTAL"}],"summary":"This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis. Participants who have completed the core study WA19926 are eligible to participate. Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)","timeFrame":"End of Study (Week 104 or early withdrawal)","effectByArm":[{"arm":"Tocilizumab","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":3,"countries":["Hungary"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Nasopharyngitis","Diarrhoea","Dermatitis","Ranula","Cystitis"]}}